The FCF Life Sciences crew constantly analyses the present sentiments within the European life sciences enterprise capital funding sector.
For August ’22, enterprise capital funding continues to say no. All life sciences subsectors (i.e. Biotech, HealthTech, and MedTech) are at present affected.
Based on our evaluation, we anticipate this downward pattern to persist within the coming months.